ACXP (Acurx Pharmaceuticals) Issuance of Debt : $0.00 Mil (TTM As of Sep. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Acurx Pharmaceuticals Issuance of Debt?

Acurx Pharmaceuticals's Issuance of Debt for the three months ended in Sep. 2024 was $0.00 Mil.

Acurx Pharmaceuticals's Issuance of Debt for the trailing twelve months (TTM) ended in Sep. 2024 was $0.00 Mil.

Acurx Pharmaceuticals Issuance of Debt Historical Data

The historical data trend for Acurx Pharmaceuticals's Issuance of Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Acurx Pharmaceuticals Issuance of Debt Chart

Acurx Pharmaceuticals Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Issuance of Debt

0.07

Acurx Pharmaceuticals Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Issuance of Debt	Get a 7-Day Free Trial															-	-	-	-	-

Acurx Pharmaceuticals Issuance of Debt Calculation

Issuance of Debt represents all the cash inflow from debt, including both long-term debt and short-term debt.

Issuance of Debt for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

Acurx Pharmaceuticals Issuance of Debt Related Terms

Thank you for viewing the detailed overview of Acurx Pharmaceuticals's Issuance of Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Acurx Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Acurx Pharmaceuticals Inc (NAS:ACXP) » Definitions » Issuance of Debt

Comparable Companies

Traded in Other Exchanges

3ZO:Germany

Address

259 Liberty Avenue, Staten Island, NY, USA, 10305

Website

https://www.acurxpharma.com

Acurx Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing a new class of antibiotics for infections caused by bacteria listed as priority pathogens by the World Health Organization, Centers for Disease Control and Prevention and Food and Drug Administration.

Executives

David P Luci	director, 10 percent owner, officer: President and CEO
Robert J Deluccia	director, 10 percent owner	40 WASHINGTON STREET, SUITE 220, WELLESLEY HILLS MA 02481
Carl Sailer	director	4 GREENBRIAR LANE, MONTVALE NJ 07645
Thomas L Harrison	director
Joseph C Scodari	director	JOHNSON & JOHNSON, ONE JOHNSON & JOHNSON PLAZA, NEW BRUNSWICK NJ 08933
Jack H Dean	director	C/O RESEARCH PHARMACEUTICAL SERVICES,INC, 520 VIRGINIA DRIVE, FORT WASHINGTON PA 19034
Robert G. Shawah	officer: Chief Financial Officer	C/O DIPEXIUM PHARMACEUTICALS, LLC, 74 BROAD STREET, NEW YORK NY 10004
James J. Donohue	director	C/O ACURX PHARMACEUTICALS, INC., 259 LIBERTY AVENUE, STATEN ISLAND NY 10305